Platinum-refractory Epithelial Ovarian Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-08-28
Clinical Trial Update: Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer [Phase 2]
Phase 2 clinical trial update examining etoposide capsules plus bevacizumab, iparomlimab, and tuvonralimab for platinum-resistant or platinu…
CLINICAL_TRIALS trial_result · 2014-03-07
Clinical Trial Update: Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor [Phase 2]
Phase 2 randomized multicenter trial evaluating SU11248 (sunitinib) in platinum-refractory epithelial ovarian cancer and peritoneal cancers,…